AI-Driven Drug Discovery: Unravelling the Potential of Generative Adversarial Networks (GANs) in Pharmaceutical Research

This paper examines how AI has revolutionised drug development and medical research using the ChEMBL dataset. The primary study areas are AI-driven therapeutic target identification., computational approaches in drug development., drug repurposing for COVID-19 therapies., and AI methods for natural leather flaw detection. Target selection must balance novelty and confidence., and AI-driven therapeutic target identification is considered. Structure-based virtual screening and profound learning predictions of ligand properties and target activities are considered for application in scaling up to broader chemical spaces. AI is used to discover new links between drugs., targets., and diseases and treat COVID-19. The paper also highlights this field's enforcement challenges and offers solutions. A Generative Adversarial Network (GAN)-based automatic flaw identification system for natural leather is another topic of study. The results show that the suggested strategy is economical and accurate., despite limitations and biases. AI has revolutionised medical diagnostics., medication development., and precision medicine., making this work meaningful. This paper”s findings offer a cross-disciplinary perspective on artificial intelligence's potential in healthcare., revealing knowledge gaps and suggesting further research.